2023年1月10日 · 2022年，恩格列净先后获批用于治疗射血分数降低的心力衰竭（HFrEF）和 射血分数保留的心力衰竭（HFpEF），标志着恩格列净成为首个可用于治疗全射血分数慢性HF的钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）。 调查显示，全球范围内超过6000万人患有心力衰竭（HF）[3]，HF是导致患者住院的主要原因之一[4,5]，也是导致＞65岁人群住院的首要原因[6]。 因心力衰竭住院（HHF）后90天内的再入院率约高达30%[7]，且约有30% HHF患者在1年内死 …

2023年9月27日 · 《2023ESC急性和慢性心力衰竭 (心衰)诊断和治疗指南焦点更新》 (简称《2023ESC焦点更新》)涉及慢性心衰[主要为射血分数保留的心衰 (HFpEF)和射血分数轻度降低的心衰 (HFmrEF)]、急性心衰、心衰合并症，以及心衰药物应用，主要为钠-葡萄糖共转运蛋白2抑制剂 (SGLT-2i)。 ESC急性和慢性心衰指南 (简称ESC指南)通常以5年为一个周期，用于指导此后5年的心衰管理。 在2021年ESC指南发表后仅隔2年便进行若干更新，实属罕见。 但又在情理之 …

In patients with HF and LVEF>40%, the quadruple combination of ARNI, BB, MRA, and SGLT2i provides the largest reduction in the risk of CV death and HHF; driven by the robust effect of the triple combination of ARNI, MRA, and SGLT2i. The benefit was more pronounced in …

2023年8月2日 · The purpose of this paper is to provide a contemporary overview on hypertensive HF (HHF), defined as the presence of HF symptoms and signs in a patient with a history of HTN and elevated systolic blood pressure (BP) at presentation (≥130 mmHg) in the absence of an acute coronary syndrome or a history of it, and hemodynamically significant ...

The purpose of this paper is to provide a contemporary overview on hypertensive HF (HHF), defined as the presence of HF symptoms and signs in a patient with a history of HTN and elevated systolic blood pressure (BP) at presentation (≥130 mmHg) in the absence of an acute coronary syndrome or a history of it, and hemodynamically significant ...

2024年9月16日 · SPIRRIT-HFpEF is a multicentre, prospective, randomized, open-label, blinded endpoint trial conducted on platforms in the Swedish Heart Failure Registry (SwedeHF) and the United States (US) Trial Innovation Network. Patients with HFpEF/HFmrEF are randomized 1:1 to spironolactone (or eplerenone) in addition to usual care, versus usual care alone.

本文通过对HFrEF、HFmrEF及HFpEF的流行病学、临床特征、病理生理学、预后及治疗等方面进行总结分析，发现HFmrEF可能是HFrEF及HFpEF的中间和过渡型。 目前在HFmrEF诊疗策略的多个方面仍有待进一步验证，比如更积极地抗心肌缺血治疗及射血分数动态监测对心肌细胞的保护价值；心血管和非心血管疾病合并症的筛查协助认识HFmrEF病理生理特征的临床价值；心脏磁共振成像检查对 HFmrEF 病理生理学改变的诊断价值；C端成纤维细胞生长因子23（cFGF23）和 …

Medical treatment for heart failure with preserved ejection (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF) has weaker evidence compared with reduced ejection fraction, despite recent trials with an angiotensin receptor neprilysin inhibitor (ARNI) and sodium glucose co-transporter 2 inhibitors (SGLT2is).

2023年3月1日 · To provide a pooled effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF: ≥50%) or/and mildly reduced EF (HFmrEF: 41–49%) regardless of baseline diabetes.

2024年11月23日 · ACEI + BB + MRA + SGLT2i were proven to be the most effective in reducing all-cause death (RR,0.51; 95%CI, 0.38–0.67), CV death (RR,0.46; 95%CI, 0.33–0.66), and HHF (RR,0.27; 95%CI, 0.18–0.39), followed by ACEI + BB + MRA + Ivabradine, and ARNI + BB or ACEI + BB + MRA (for HHF specifically).